



RAPID ALERT

DRAP ALERT NO. N° I/S/06-24-27

CRACKDOWN AGAINST SPURIOUS/FALSIFIED DRUG PRODUCTS

Date: 14th June, 2024.

Target Audience:

- Regulatory Field Force
- Healthcare Professionals- Surgeons, Pharmacists, and Nurses
- Pharmacists and Chemists at Distribution, Institutional suppliers
- General Public

Problem Statement:

Directorate of Drugs Control (DDC) Punjab vide Alert No. 137/2024 has informed that the following samples of drug products have been declared as “Spurious” by Drug Testing Laboratories (DTL) Multan, Lahore, Rawalpindi, and Faisalabad. Details of affected products are as follows:

S#	Product Name	Batch No.	Purported to be Manufactured by (as per label)	Result
01	Powder Amox 500 (1kg) (veterinary use)	0010823	Imported by: M/s. Brand Station, House No. 69, Woodland villas near Valencia, Raiwind Lahore. Mfg. by: M/s. The North Star Import Export Joint Stock Company, Can Tho City, Vietnam.	Spurious
02	Nutricare Syrup 450ml	NC-457	M/s. Care Pharmaceuticals.	Spurious
03	Velosef 500mg Capsule	847M	M/s. GSK, Karachi.	Spurious
04	Pyodine Solution 60ml	04813	M/s. Brookes Pharma, Karachi.	Spurious
05	Pyodine Solution 450ml	08913	M/s. Brookes Pharma, Karachi.	Spurious
06	Tanzo 0.5g Injection	PN220142	M/s. Bosch Pharmaceuticals, Karachi.	Spurious
07	Dydowen 10mg Tablet	736	M/s. Weather Fold Pharmaceuticals, Hattar.	Spurious
08	Duphaston 10mg Tablet	230672 230092	Mfg. by: Highnoon Laboratories Lahore. Mfg for: Abbott Laboratories, Karachi.	Spurious
09	Cefspan 400mg Capsule	D6780	M/s. Barrett Hodgson Pakistan, Karachi.	Spurious
10	Phenobar 30mg Tablet	QA023	M/s. Star Laboratories, Lahore.	Spurious





Threats to Public Health: -

The use of these falsified products will result in the ineffective treatment of patients. Moreover, the safety and quality of the falsified products referenced in this alert are also unknown.

Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain system including healthcare facilities to confiscate/seize this product from the market without any delay. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock to halt the distribution/supply of this product. Information related to the supplier of this product should be provided to the Regulatory field force (DRAP, Provincial Health Departments, and States) to ensure the removal of this product.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance at hospitals and within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this product.

Adverse reactions or quality problems experienced with the use of this product shall be reported to the National Pharmacovigilance Centre (NPC), DRAP using [Adverse Event Reporting Form](#) or online through this [link](#). Further information on reporting problems to DRAP is available on this [link](#).

Advice for Consumers / General public: -

Consumers should not use this product and shall contact their physician or healthcare provider if they have experienced any problem related to taking or using this drug product, and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.



Drug Regulatory Authority of Pakistan

محفوظ، موثر اور معیاری اشیائے علاج



DRAP, Islamabad



+ 92 51 910 73 17



gsms@dra.gov.pk